About Savara Pharma
Savara Pharma is a publicly listed company based in Austin (United States) founded in 2008. Therapeutics for rare respiratory diseases are developed by Savara Pharma. Savara Pharma has raised $67.82 million across 14 funding rounds from investors including Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum. The company has 59 employees. Savara Pharma has completed 1 acquisition, including Serendex Pharmaceuticals. Its chief executive, as recorded, is Matt Pauls. Savara Pharma offers products and services including MOLBREEVI. Its focus areas include Life Sciences, Pulmonology, Drugs and Lung Infections. Its legal entity is Savara Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Savara Pharma was founded in 2008 and is headquartered in Austin, United States. Operations are centered in the biotechnology sector, where therapeutics for rare respiratory diseases are developed. The lead product, molgramostim nebulizer solution, is formulated as an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) targeted at autoimmune pulmonary alveolar proteinosis (aPAP). Focus remains on advancing treatments for underserved pulmonary conditions.
- Headquarters Austin, United States
- Employees 59
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website savarapharma.com
- Social LinkedIn
- Legal Name Savara, Inc.
- Net Profit-$118.84 M (USD)-23.94as on Dec 31, 2025
- EBITDA-$123.3 M (USD)-19.8as on Dec 31, 2025
- Total Equity Funding$67.82M (USD)
in 14 rounds
- Latest Funding Round$27M (USD), Post-IPO
Dec 2019
- InvestorsTexas.gov
& 10 more
- Employee Count59
- Investments & Acquisitions
Products & Services of Savara Pharma
Savara Pharma offers a comprehensive portfolio of products and services, including MOLBREEVI.
Inhaled recombinant GM-CSF for treating autoimmune pulmonary alveolar proteinosis.
Funding Insights of Savara Pharma
Savara Pharma has successfully raised a total of $67.82M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $27 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.82M
- Total Rounds 14
- Last Round Post-IPO — $27M
- First Round $833,000
(Jun 2009)
- Investors Count 11
Latest 10 of 14 funding rounds of Savara Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $27M | Post-IPO | – | – | |
| Dec 2017 | $5M | Post-IPO | – | – | |
| Feb 2016 | $20.67M | Series C | – | – | – |
| Oct 2014 | $10M | Series C | – | – | – |
| Jun 2014 | $4.49M | Series B | – | – | – |
| Oct 2013 | $1.7M | Grant | – | – | |
| Jun 2013 | $14.4M | Series B | – | – | |
| Mar 2013 | $7.4M | Series B | – | – | |
| Mar 2013 | $4M | Grant | – | – | |
| Jun 2012 | $8.6M | Series B | – | – | – |
11 investors in total: 11 institutional.
Investors in Savara Pharma
Savara Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Accredited investors are networked for private equity funding opportunities. | 2000 | keiretsuforum.com | San Francisco, United States | |
Angel Network for companies based in Southern California | techcoastangels.com | Los Angeles, United States | ||
| centraltexasangelnetwork.com | ||||
Early-stage companies are supported through angel investment funding. | northtexasangels.org | Dallas, United States | ||
Deep tech commercialization is facilitated by Austin Technology Incubator. | 1989 | ati.utexas.edu | Austin, USA | |
| ecor1cap.com | ||||
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
Research on heart, lung, blood, and sleep disorders is conducted. | nhlbi.nih.gov | Bethesda, United States |
Investor details for Savara Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Savara Pharma
39 people are tracked at Savara Pharma (23 in leadership, 9 in board & advisors, 7 in team); the tracked headcount is 59.
| Name | Role | Group |
|---|---|---|
Matt Pauls | CEO | Leadership |
Dave Lowrance | Chief Financial & Administrative Officer | Leadership |
Anne Erickson | Chief Business Officer | Leadership |
Patricia A. Lufburrow | Senior Vice President | Leadership |
Lisa Fleury | Vice President Of Market Access | Leadership |
Matthew Pauls | Chair & CEO | Leadership |
Ray Pratt | Chief Medical Officer | Leadership |
Kate McCabe | Chief Legal Officer | Leadership |
Robert Lutz | COO | Leadership |
Paul Gratt | Head Of Market Development | Leadership |
Stephanie J. Harris | Director Of Project Management | Leadership |
Patti Smith M.s. | Senior Director, Head Of North America Regulatory Affairs | Leadership |
Danielle Brown | Corporate Controller And Executive Director Of Accounting | Leadership |
Sandra Gallagher | Vice President Business Operations | Leadership |
Michele Irwin Cunningham | Senior Vice President, Global Commercial Operations | Leadership |
Brian Maurer | Head Of Clinical Operations | Leadership |
Braden Parker | Chief Commercial Officer (cco) | Leadership |
Susi Antoniuk | Director Regulatory Affairs | Leadership |
Heather King | Senior Director, US Commercial | Leadership |
John Lombardo | Executive Director, Logistics & Supply Chain | Leadership |
19 more people are available in the full profile.
Complete people profiles for Savara Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Savara Pharma
Savara Pharma is a publicly listed company on the NASDAQ with ticker symbol SVRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Apr 2017
- Listed onNASDAQ: SVRA
- Listed entitySavara, Inc.
- Exchange sectorHealth technology
- ISINUS8051111016
- Share price$4.78 (-1.24% on the day) · 2026-10-13
- Market capitalisation$982.1M
- EPS (diluted, trailing year)$-0.58
- Volume (last session)3,742,181
Financials of Savara Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$118.8M | -$123.3M | |
| 2024 | -$95.9M | -$102.9M | |
| 2023 | -$54.7M | -$59.8M | |
| 2022 | -$38.1M | -$38.7M | |
| 2021 | -$43.0M | -$41.1M |
Detailed financial statements for Savara Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Savara Pharma
Savara Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Serendex Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical drug development company focusing on respiratory conditions | serendex.com | Copenhagen, Denmark | 2008 | Jul 2016 | •••• |
Complete acquisition details for Savara Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Savara Pharma
5 dated milestones of Savara Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Savara Pharma is founded.
- Funding First funding round of $833K.
- Acquisition Acquires Serendex Pharmaceuticals.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $27.0M.
Competitors of Savara Pharma
Savara Pharma has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Savara Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Savara Pharma
The website of Savara Pharma (savarapharma.com) receives about 4K visits a month and ranks #3,870,989 among all websites worldwide, #4,922 in Biotechnology and Pharmaceuticals.
- Monthly visits4K
▼ 16.1% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,870,989
among all websites
- Category rank#4,922
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.8
- Average visit1 min 54 sec
- DevicesDesktop 59% · Mobile 41%
Websites whose visitors overlap most with Savara Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alderbio.com | 100% | View details | |||
| veronapharma.com | 93% | 7.7K | #2,500,388 | View details | |
| ultragenyx.com | 92% | 52.6K | #608,406 | View details | |
janssen-cilag.com | janssen-cilag.com | 92% | – | ||
pneumotox.com | pneumotox.com | 58% | #2,245,082 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Savara Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Savara Pharma (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Savara Pharma
Complete news archive for Savara Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Savara Pharma
Savara Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Savara Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Matt Pauls is the CEO of Savara Pharma, as recorded in our data.
Savara Pharma is a funded company, having raised a total of $67.82M across 14 funding rounds to date. The company's 1st funding round was a Series B of $8.6M, raised on Jun 2009.
Savara Pharma has 59 employees.
Savara Pharma was founded in 2008 and is headquartered in Austin, United States. Operations are centered in the biotechnology sector, where therapeutics for rare respiratory diseases are developed. The lead product, molgramostim nebulizer solution, is formulated as an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) targeted at autoimmune pulmonary alveolar proteinosis (aPAP). Focus remains on advancing treatments for underserved pulmonary conditions.
Savara Pharma's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Savara Pharma offers MOLBREEVI.
Yes, Savara Pharma is publicly traded on NASDAQ under the ticker symbol SVRA.
Savara Pharma has made 1 acquisition, including Serendex Pharmaceuticals.
Savara Pharma has 11 investors. Key investors include Texas.gov, Cystic Fibrosis Foundation, Keiretsu Forum, EcoR1, and Logos Capital.
Savara Pharma operates through Savara Inc..